AstraZeneca's Mood Lifting; Targacept Gets Sunny, Too

Targacept Inc.'s partner AstraZeneca plc last week talked up TC-5214, the adjunctive compound for major depressive disorder that just entered Phase III trials, giving nervous investors hope in the pharma giant, which will see the patent expire on Seroquel IR (quetiapine) in March 2012.